LAVAL, Quebec, Nov. 20, 2015 /CNW/ -- Valeant
Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX)
announced that the Company will be hosting an Investor Day on
December 16, 2015 where the Company
will be providing updated financial guidance, discussing certain
business operations and highlighting certain R&D programs.
Conference Call and Webcast Information
The dial-in number to participate on this call is (877)
876-8393, confirmation code 86470820. International callers
should dial (973) 200-3961, confirmation code 86470820. A replay
will be available following the conclusion of the conference call
through December 23, 2015, and can be
accessed by dialing (855) 859-2056 or (404) 537-3406, confirmation
code 86470820.
The webcast and slide presentation will be hosted in the
investor relations section of its corporate website at
www.valeant.com. Participants should allow approximately five to
ten minutes prior to the call's start time to visit the site and to
download any streaming media software needed to listen to the
webcast. An online archive of the webcast will be available
following the end of the live call in the webcast archive portion
of the investor relations section at www.valeant.com.
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a
multinational specialty pharmaceutical company that develops,
manufactures and markets a broad range of pharmaceutical products
primarily in the areas of dermatology, gastrointestinal disorder,
eye health, neurology and branded generics. More information about
Valeant can be found at www.valeant.com.
Forward-looking Statements
This press release may contain forward-looking statements,
including, but not limited to, statements regarding Valeant's
intent to hold an Investor Day, provide updated financial guidance,
discuss certain business operations and highlight certain R&D
programs. Forward-looking statements may generally be identified by
the use of the words "anticipates," "expects," "intends," "plans,"
"should," "could," "would," "may," "will," "believes," "estimates,"
"potential," "target," or "continue" and variations or similar
expressions. These statements are based upon the current
expectations and beliefs of management and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include, but are not limited to,
risks and uncertainties discussed in the Company's most recent
annual or quarterly report and detailed from time to time in
Valeant's other filings with the Securities and Exchange
Commission and the Canadian Securities Administrators, which
factors are incorporated herein by reference. Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Valeant undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this press release or to reflect
actual outcomes, unless required by law.
Contact Information:
Laurie W.
Little
949-461-6002
laurie.little@valeant.com
Elif McDonald
905-695-7607
elif.mcdonald@valeant.com
Media:
Renee E. Soto/Meghan Gavigan
Sard Verbinnen & Co.
212-687-8080
rsoto@sardverb.com / mgavigan@sardverb.com
Logo -
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/valeant-to-hold-investor-day-on-december-16-300182327.html
SOURCE Valeant Pharmaceuticals International, Inc.